Letters Rosiglitazone saga

Authors’ reply

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d2573 (Published 21 April 2011) Cite this as: BMJ 2011;342:d2573
  1. Yoon Kong Loke, senior lecturer in clinical pharmacology1,
  2. Chun Shing Kwok, medical student1,
  3. Sonal Singh, assistant professor of medicine2
  1. 1School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK
  2. 2Johns Hopkins University School of Medicine, Baltimore, MD, USA
  1. y.loke{at}uea.ac.uk

Heazlewood describes the modest evidence for pioglitazone’s beneficial effect on a composite cardiovascular end point but fails to mention the inconclusive data on individual end points, such as myocardial infarction (relative risk 0.81, 95% confidence interval 0.64 to 1.02; P=0.08) or death (0.92, 0.76 to 1.11; P=0.38) compared with non-thiazolidinedione …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe